Aufgepasst, möcht mal eine unbekannte Perle vorstellen... - 500 Beiträge pro Seite
eröffnet am 06.02.06 08:41:25 von
neuester Beitrag 09.02.06 23:03:03 von
neuester Beitrag 09.02.06 23:03:03 von
Beiträge: 2
ID: 1.038.066
ID: 1.038.066
Aufrufe heute: 0
Gesamt: 728
Gesamt: 728
Aktive User: 0
Top-Diskussionen
Titel | letzter Beitrag | Aufrufe |
---|---|---|
vor 17 Minuten | 5673 | |
vor 10 Minuten | 4609 | |
vor 22 Minuten | 3870 | |
vor 1 Stunde | 3321 | |
vor 52 Minuten | 2383 | |
heute 14:53 | 1926 | |
vor 1 Stunde | 1767 | |
heute 13:07 | 1416 |
Meistdiskutierte Wertpapiere
Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
---|---|---|---|---|---|---|---|
1. | 1. | 18.166,36 | +1,32 | 225 | |||
2. | 2. | 1,1300 | -18,12 | 119 | |||
3. | 3. | 0,1905 | +0,79 | 105 | |||
4. | 5. | 9,2850 | +0,43 | 76 | |||
5. | 4. | 168,48 | -1,00 | 57 | |||
6. | Neu! | 11,905 | +14,97 | 38 | |||
7. | Neu! | 4,7610 | +6,15 | 36 | |||
8. | Neu! | 0,4250 | -1,16 | 36 |
Advancis Pharmaceutical Corporation wird diese Woche Donnerstag die vorläufigen Zahlen vorstellen. Die Aktie ist tief gefallen und befindet sich nun seit Wochen nachhaltig in einem Aufwärtstrend. Das Kürzel ist AVNC und die WKN: 358054, handelbar in München. Hier steckt noch jede Menge Kursphantasie, denn die Zahlen am Donnerstag werden sicher nicht enttäuschen, sonst würden die das nicht so ankündigen und vor allem scheint es, als wenn ein paar in den USA das schon "AHNEN" würden. Aber lest selber und schaut Euch den Chart an!!! Hab am Freitag schon drauf aufmerksam gemacht, jetzt nochmal, kaufen. Viel Glück und recherchiert mal richtig. Sieht wirklich gut aus. Gruß. Der,der Euch viel Geld wünscht.
Advancis Pharmaceutical to Announce Fourth Quarter and Full Year 2005 Financial Results on February 9, 2006
E-mail or Print this story
3 February 2006, 12:29pm ET
Conference Call and Webcast to Follow
GERMANTOWN, Md., Feb. 3 /PRNewswire-FirstCall/ -- Advancis Pharmaceutical Corporation (Nasdaq: AVNC), a pharmaceutical company focused on developing and commercializing novel anti-infective products, today announced it will release results for the quarter and fiscal year ended December 31, 2005, on Thursday, February 9, 2006, before the market opens. A full text copy of the release will be disseminated at that time.
Edward M. Rudnic, Ph.D., president and chief executive officer, will host a conference call to discuss the results and other corporate developments at 10:30 AM ET on Thursday, February 9, 2006. Also participating on the call will be Robert Low, vice president, finance and acting CFO. To participate in the conference call, dial the appropriate number below shortly before the 10:30 AM start time and ask for the Advancis Pharmaceutical conference call hosted by Dr. Rudnic.
The teleconference dial-in numbers are as follows:
Domestic callers 1-800-813-8504
International callers 1-706-643-7752
The conference call will be broadcast simultaneously and archived on the Company`s web site, http://www.advancispharm.com . Investors should go to the web site at least 15 minutes early to register, download, and install any necessary audio software.
Mentioned Last Change
AVNC 1.95 0.11dollars or (5.97%)
A replay of the call will be available on Thursday, February 9, 2006, beginning at 12:30 PM ET and will be accessible until Thursday, February 16, 2006, at 5:00 PM ET. The replay call-in number is 1-800-642-1687 for domestic callers and 1-706-645-9291 for international callers. The access number is 4594709.
About Advancis Pharmaceutical:
Advancis Pharmaceutical Corporation (Nasdaq: AVNC) is a pharmaceutical company focused on the development and commercialization of pulsatile drug products that fulfill substantial unmet medical needs in the treatment of infectious disease. The Company is developing anti-infective drugs based on its novel biological finding that bacteria exposed to antibiotics in front- loaded staccato bursts, or "pulses," are killed more efficiently than those under standard treatment regimens. Based on this finding, Advancis has developed a proprietary, once-a-day pulsatile delivery technology called PULSYSTM. By examining the resistance patterns of bacteria and applying its delivery technologies, Advancis has the potential to redefine infectious disease therapy and significantly improve drug efficacy, shorten length of therapy, and reduce drug resistance versus currently available antibacterial products. For more on Advancis, please visit http://www.advancispharm.com .
SOURCE Advancis Pharmaceutical Corporation
-0- 02/03/2006
/CONTACT: Bob Bannon, Senior Director, Investor Relations of Advancis
Pharmaceutical Corporation, +1-301-944-6710,
rbannon@advancispharm.com
/
/Web site:
http://www.advancispharm.com
/
(AVNC)
CO: Advancis Pharmaceutical Corporation
ST: Maryland
IN: HEA MTC
SU: CCA
AR-LM
-- DCF029 --
1136 02/03/2006 12:29 EST
http://www.prnewswire.com
Advancis Pharmaceutical to Announce Fourth Quarter and Full Year 2005 Financial Results on February 9, 2006
E-mail or Print this story
3 February 2006, 12:29pm ET
Conference Call and Webcast to Follow
GERMANTOWN, Md., Feb. 3 /PRNewswire-FirstCall/ -- Advancis Pharmaceutical Corporation (Nasdaq: AVNC), a pharmaceutical company focused on developing and commercializing novel anti-infective products, today announced it will release results for the quarter and fiscal year ended December 31, 2005, on Thursday, February 9, 2006, before the market opens. A full text copy of the release will be disseminated at that time.
Edward M. Rudnic, Ph.D., president and chief executive officer, will host a conference call to discuss the results and other corporate developments at 10:30 AM ET on Thursday, February 9, 2006. Also participating on the call will be Robert Low, vice president, finance and acting CFO. To participate in the conference call, dial the appropriate number below shortly before the 10:30 AM start time and ask for the Advancis Pharmaceutical conference call hosted by Dr. Rudnic.
The teleconference dial-in numbers are as follows:
Domestic callers 1-800-813-8504
International callers 1-706-643-7752
The conference call will be broadcast simultaneously and archived on the Company`s web site, http://www.advancispharm.com . Investors should go to the web site at least 15 minutes early to register, download, and install any necessary audio software.
Mentioned Last Change
AVNC 1.95 0.11dollars or (5.97%)
A replay of the call will be available on Thursday, February 9, 2006, beginning at 12:30 PM ET and will be accessible until Thursday, February 16, 2006, at 5:00 PM ET. The replay call-in number is 1-800-642-1687 for domestic callers and 1-706-645-9291 for international callers. The access number is 4594709.
About Advancis Pharmaceutical:
Advancis Pharmaceutical Corporation (Nasdaq: AVNC) is a pharmaceutical company focused on the development and commercialization of pulsatile drug products that fulfill substantial unmet medical needs in the treatment of infectious disease. The Company is developing anti-infective drugs based on its novel biological finding that bacteria exposed to antibiotics in front- loaded staccato bursts, or "pulses," are killed more efficiently than those under standard treatment regimens. Based on this finding, Advancis has developed a proprietary, once-a-day pulsatile delivery technology called PULSYSTM. By examining the resistance patterns of bacteria and applying its delivery technologies, Advancis has the potential to redefine infectious disease therapy and significantly improve drug efficacy, shorten length of therapy, and reduce drug resistance versus currently available antibacterial products. For more on Advancis, please visit http://www.advancispharm.com .
SOURCE Advancis Pharmaceutical Corporation
-0- 02/03/2006
/CONTACT: Bob Bannon, Senior Director, Investor Relations of Advancis
Pharmaceutical Corporation, +1-301-944-6710,
rbannon@advancispharm.com
/
/Web site:
http://www.advancispharm.com
/
(AVNC)
CO: Advancis Pharmaceutical Corporation
ST: Maryland
IN: HEA MTC
SU: CCA
AR-LM
-- DCF029 --
1136 02/03/2006 12:29 EST
http://www.prnewswire.com
Holle72...deine Postings sind ja irgendwie interessant.Aber mach Dir doch mal die Mühe diese sogenannte Perle auf hochdeutsch vorzustellen.Nicht jeder ist so intelligent,englischesprachige Ergebniszahlen zu entschlüsseln,geschweige denn zu beurteilen.Gruss Apta
Beitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
Wertpapier | Beiträge | |
---|---|---|
225 | ||
119 | ||
105 | ||
76 | ||
57 | ||
38 | ||
36 | ||
36 | ||
33 | ||
31 |
Wertpapier | Beiträge | |
---|---|---|
28 | ||
22 | ||
18 | ||
18 | ||
18 | ||
17 | ||
17 | ||
17 | ||
16 | ||
16 |